<DOC>
	<DOC>NCT01633788</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of AGN-195263 compared to vehicle in patients with meibomian gland dysfunction (MGD) in the eyelids.</brief_summary>
	<brief_title>A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction</brief_title>
	<detailed_description />
	<criteria>Meibomian gland dysfunction in both eyes Bestcorrected visual acuity of 20/40 or better in each eye Known or suspected prostate cancer History of breast cancer Using LATISSEÂ® or any other eye lash growthstimulating product at least 30 days prior to the screening visit, or anticipated use during the study Contact lens wear in either eye during any portion of the study Unable to instill eye drops correctly History of corneal refractive surgery in either eye within 1 year</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>